Abstracts tagged "infection and rheumatoid arthritis (RA)"

Abstract Number: 471 • 2016 ACR/ARHP Annual Meeting
Epstein-Barr Virus-Induced Expression of Receptor Activator Nuclear Factor-κb Ligand on B Cells Is Possibly Responsible for Erosive Arthritis in Epstein-Barr Virus-Infected Humanized Nonobese Diabetic/Shi-Scid/γcnull Mice
Mitsuhiro Iwata¹, Yosuke Nagasawa¹, Noboru Kitamura¹, Takamasa Nozaki¹, Eiko Ishizuka¹, Ken-Ichi Imadome², Shigeyoshi Fujiwara³ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Advanced Medicine for Virus Infections, National Research Institute for Child Health and Development, Tokyo, Japan, ³Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose: Humanized nonobese diabetic/Shi-scid/γcnull (NOG) mice, which are reconstituted with human hematoimmune system by transplantation with human CD34＋ hematopoietic stem cells (termed as humanization), have…
Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Karen Ferez-Blando¹, Hilda Fragoso-Loyo², Alfredo Ponce de León³, Sergio Ponce de Leon-Rosales⁴ and Yemil Atisha-Fregoso¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…
Abstract Number: 1505 • 2016 ACR/ARHP Annual Meeting
Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Sadao Jinno¹, Na Lu^2,3, S. Reza Jafarzadeh⁴ and Maureen Dubreuil^3,5, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁴Medicine, Washington University School of Medicine, St Louis, MO, ⁵Rheumatology, Boston VA HealthCare System, Boston, MA
Background/Purpose: With the increasing uptake of RA treatments that confer infection risk, an increase in the rates of infection hospitalizations among RA patients is expected,…
Abstract Number: 35 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study
Mette Holland-Fischer¹, Ulrik Tarp², Reimar W. Thomsen³ and Mette Nørgaard³, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, AArhus, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with Rheumatoid Arthritis (RA). Patients with RA do also have an increased…
Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting
Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Jeffrey R. Curtis¹, Marc de Longueville², Cathy O'Brien² and Boulos Haraoui³, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Brussels, Belgium, ³Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
Abstract Number: 610 • 2015 ACR/ARHP Annual Meeting
Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy
Hyun Mi Kwon, Sang Jin Lee, Ji Ae Yang, Jin Young Moon, Eun Young Ahn, Jin Kyun Park, Eun Young Lee, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) infection. RA treatment including immunosuppressant medications could further exacerbate the risk.…
Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting
The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years
Jean-Jacques Dubost¹, Bruno Pereira², Anne Tournadre³, Zuzana Tatar¹, Marion Couderc¹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 1995 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?
Sofia Pedro¹, Ted R. Mikuls² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Elderly-onset RA (EORA) patients (age of onset>60) are less likely to be treated with biologics even when accounting for disease activity compared to young-onset…
Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting
Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
Huifeng Yun¹, Lang Chen², George W. Reed³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Corrona, LLC., Southborough, MA, ⁴Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…
Abstract Number: 2151 • 2014 ACR/ARHP Annual Meeting
Abatacept Related Infections: No Association with Gammaglobulin Reduction
Valquiria Dinis¹, Vilma S. T. Viana¹, Elaine P. Leon¹, Clovis A Silva², Carla G.S. Saad³, Julio C. B. Moraes³, Eloisa Bonfá³ and Ana C.M. Ribeiro⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose A recent study reported that abatacept (ABA) reduces rheumatoid arthritis (RA) related autoantibodies and gammaglobulins levels. However, the possible association of these findings with…
Abstract Number: 820 • 2014 ACR/ARHP Annual Meeting
Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination
Huifeng Yun¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Kevin L. Winthrop⁵, John Baddley³, Kenneth G. Saag⁶, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁸, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Herpes zoster (HZ) vaccine is recommended for healthy people age >= 60 years in US. It is unclear whether the absolute risk for younger…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 467 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort
Lucia Silva-Fernandez^1,2, Mark Lunt¹, Kath D. Watson¹, . BSRBR Control Centre Consortium¹, Deborah P. Symmons¹, Kimme Hyrich¹ and . On behalf of the BSRBR³, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³British Society for Rheumatology, London, United Kingdom
Background/Purpose: Serious infections (SI) are a major concern in patients treated with tumour necrosis factor inhibitors (TNFi). The RABBIT Risk Score (RRS) (1) allows a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].